Duchenne expert physician perspectives on Duchenne newborn screening and early Duchenne care

Duchenne muscular dystrophy (DMD) is a progressive, fatal neuromuscular disorder typically diagnosed between 4 and 5 years of age. DMD currently has five FDA approved therapies, which has led to increased interest in newborn screening (NBS) for DMD. Our objective was to explore the perspectives and...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Niki, Schrader, Rachel, Fischer, Ryan, Crossnohere, Norah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804401/
https://www.ncbi.nlm.nih.gov/pubmed/35932090
http://dx.doi.org/10.1002/ajmg.c.31993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804401/
https://www.ncbi.nlm.nih.gov/pubmed/35932090
http://dx.doi.org/10.1002/ajmg.c.31993

Ejemplares similares